Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
ECDC provides support to EU/EEA countries in monitoring their progress towards the hepatitis elimination targets and has just published a report based on the second data collection.
Yellow fever (YF) is a mosquito-borne infection, distributed in west, central and east Africa and in South America. The disease can cause a wide spectrum of symptoms, from mild to fatal. In severe cases there may be spontaneous haemorrhage. Mortality of these clinical cases can be as high as 80%, on a par with Ebola, Marburg and other haemorrhagic viral infections.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 30 August - 5 Sep 2020 and includes updates on COVID-19, Ebola virus disease, MERS, Dengue, CCHF, West Nile Virus.
Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and European Economic Area (EU/EEA) and the UK have not yet been diagnosed. This is a major obstacle on the way towards the Sustainable Development Goal (SDG) for health in 2030 as highlighted by ECDC on occasion of World Hepatitis Day.